This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
Tim Wilsdon moderates the session discussing how to fast-track policy solutions that could address the barriers preventing patient access to NGS and identify the ones that should be prioritized.
For more information on this event, click here.
Treatment choice is beneficial for people living with rare diseases (RDs) and competition can drive important economic advantages for payers.
In Part 3 of this series, RADAR data on orphan-drug pricing in Germany revealed a significant increase in manufacturer-set list prices for new orphan drugs...
CRA is a proud sponsor of the conference focusing on the intersection of intellectual property and the biopharmaceutical industry, and will explore the law,...
CRA is a proud sponsor of the the largest and most established orphan drug & rare disease meeting of its kind across the globe. From cell and gene therapy,...
